Targets › GAA
6 programs from 6 companies in 11 trials: 5 Phase 1, 3 Phase 4, 2 Phase 3, 1 Phase 2; Metabolic and endocrine; next expected readout Dec 2026.
Essential for the degradation of glycogen in lysosomes. Has highest activity on alpha-1,4-linked glycosidic linkages, but can also hydrolyze alpha-1,6-linked glucans. (UniProt, P10253)
Open in Phaseline: the race on GAA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sanofi | Avalglucosidase alfa (GZ402666) Lysosomal acid alpha-glucosidase (GAA) replacement therapy | GAA | Phase 4 | Glycogen Storage Disease Type II; Glycogen Storage Disease Type II-Pompe's Disease; Glycogen Storage Disease Type II Late Onset | Jun 2027 |
| Amicus Therapeutics | Cipaglucosidase Alfa (ATB200) Acid alpha-glucosidase (GAA) enzyme replacement therapy | GAA | Phase 3 | Pompe Disease (Late-onset); Glycogen Storage Disease Type II Infantile Onset | Mar 2027 |
| GeneCradle | GC301 AAV9 vector delivering functional human GAA gene | GAA | Phase 1 | Pompe Disease Infantile-Onset; Pompe Disease (Late-onset) | Dec 2026 |
| AskBio | AB-1009 GAA gene therapy delivered via recombinant adeno-associated virus (AAV) | GAA | Phase 1 | Pompe Disease (Late-onset) | Sep 2028 |
| Spark Therapeutics | SPK-3006 AAV-mediated gene transfer expressing acid alpha-glucosidase (GAA) | GAA | Phase 1 | Pompe Disease | Apr 2032 |
| Astellas | zocaglusagene nuzaparvovec (AT845) AAV8 vector delivering functional human GAA gene under muscle-specific promoter | GAA | Phase 1 | Pompe Disease (Late-onset) | Feb 2035 |
Pompe Disease (Late-onset) (4) Glycogen Storage Disease Type II (2) Pompe Disease Infantile-Onset (1) Glycogen Storage Disease Type II Infantile Onset (1) Glycogen Storage Disease Type II-Pompe's Disease (1) Glycogen Storage Disease Type II Late Onset (1) Pompe Disease (1)
other (4), mixed (1), protein or peptide (1)
Astellas (1) GeneCradle (1) Amicus Therapeutics (1) Sanofi (1) Spark Therapeutics (1) AskBio (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.